PASCAL

Principal Investigator:
Asim Yunus, MD (MCVI)

Sub-Investigators:
Teri Spear, NP
Kamran Shokoohi, MD

Sponsor:
ARYx Therapeutics

Study Purpose:
A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities.

Objective:
To study the efficacy of ATI-2042 in reducing atrial tachyarrhythmia (AT/AF) burden in patients with PAF, compared to placebo, for 12 weeks of treatment. To study the safety and tolerability of ATI-2042 for up to 12 weeks of treatment.

Status:
Active enrollment

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.

<< Back